{"id":411339,"date":"2021-01-08T16:08:11","date_gmt":"2021-01-08T21:08:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411339"},"modified":"2021-01-08T16:08:11","modified_gmt":"2021-01-08T21:08:11","slug":"ceo-dr-johnson-lau-contracts-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/","title":{"rendered":"CEO Dr. Johnson Lau Contracts COVID-19"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BUFFALO, N.Y., Jan.  08, 2021  (GLOBE NEWSWIRE) &#8212; Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex\u2019s CEO. Under the advice of his physician, he will not be able to attend the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference. Athenex\u2019s senior management team will continue to participate and present at the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference at its previously scheduled presentation time, and investor one-on-one meetings.<\/p>\n<p>\n        <strong>About\u00a0Athenex, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Founded in 2003,\u00a0Athenex, Inc.\u00a0is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer.\u00a0Athenex\u00a0is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company\u2019s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex\u2019s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex\u00a0has offices in\u00a0Buffalo\u00a0and\u00a0Clarence, New York;\u00a0Cranford, New Jersey;\u00a0Houston, Texas;\u00a0Chicago, Illinois;\u00a0Hong Kong;\u00a0Taipei,\u00a0Taiwan; multiple locations in\u00a0Chongqing, China;\u00a0Manchester, UK;\u00a0Guatemala City,\u00a0Guatemala\u00a0and\u00a0Buenos Aires, Argentina. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cUbaRJo5lC6TUrGMKZZGiJNkJLrRZlCaLX9a7mjDRqOYGsocbm_yFxTci43K6GmJPITDp_HA40WBm35uXOKpmA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.athenex.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforesee,\u201d \u201cgoal,\u201d \u201cguidance,\u201d \u201cintend,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cpreliminary,\u201d \u201cprobable,\u201d \u201cproject,\u201d \u201cpromising,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex\u2019s business; our history of operating losses and need to raise additional capital to continue as a going concern; uncertainties around our ability to meet funding conditions under our financing agreements and access to capital thereunder; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; competition; intellectual property risks; risks relating to doing business internationally and in\u00a0China; the risk of production slowdowns or stoppages or other interruptions at our\u00a0Chongqing\u00a0facilities; and the other risk factors set forth from time to time in our\u00a0SEC\u00a0filings, copies of which are available for free in the Investor Relations section of our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zgtBH8VHVN0Fik3qoOXhm_cxN5WTuyqYUQlflsaOLv5Gf49BwBuciSFss5tSnx0_cjoJVcnghGe4U-rVAh5eO09h4Ld07REAES6dPFbrUnoQNs_PFV3NHZrW1zBZIhVeCadWOui0hVqfKVp2tUM6zjSQTo5mRgoVXFyEG5Ax5yWKGxEZ7IR_Z_lFfGuCse5p\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/ir.athenex.com\/phoenix.zhtml?c=254495&amp;p=irol-sec<\/a>\u00a0or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <u>Investors<\/u>\n      <\/p>\n<p>Steve Rubis<br \/>Athenex, Inc.<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8WlRBgwCDv4P8404vV-o7gz5loZPAivgT8klujnRuwIfkAG0cYLKcM-bIiJK9stgr5fAkhZ4qPEYwt_dpvvlk5tutVWREl0J4FrbNrwYLJA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">stevenrubis@athenex.com<\/a><\/p>\n<p>Daniel Lang, MD<br \/>Athenex, Inc.<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HsfZUESQSzXMB7lT1kLlKilpdL7tZhLBDh6K-fApBuSe2Yi68EbkojDHBj9i8xz7O7WsLA3GKMK9bSleZii-M_QO0j0KHruRsyjrNYGltRU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">danlang@athenex.com<\/a><\/p>\n<p>Tim McCarthy<br \/>LifeSci Advisors, LLC<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YEFXjWegQ8CXPx9onuAEiqYpOAAXndFFvSD_etl9_IV90vagrTzjjQQ380iqVrpiqZW1b4Yjjqag5t7R8fELtSwBk_VeXPPLrbG5PG2eHF0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tim@lifesciadvisors.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8fd64207-622d-4fc9-902f-d405d2c67ef9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex\u2019s CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex\u2019s senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CEO Dr. Johnson Lau Contracts COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex\u2019s CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex\u2019s senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously &hellip; Continue reading &quot;CEO Dr. Johnson Lau Contracts COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-08T21:08:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CEO Dr. Johnson Lau Contracts COVID-19\",\"datePublished\":\"2021-01-08T21:08:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/\"},\"wordCount\":583,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/\",\"name\":\"CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\",\"datePublished\":\"2021-01-08T21:08:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-johnson-lau-contracts-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEO Dr. Johnson Lau Contracts COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk","og_description":"BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex\u2019s CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex\u2019s senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously &hellip; Continue reading \"CEO Dr. Johnson Lau Contracts COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-08T21:08:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CEO Dr. Johnson Lau Contracts COVID-19","datePublished":"2021-01-08T21:08:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/"},"wordCount":583,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/","name":"CEO Dr. Johnson Lau Contracts COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=","datePublished":"2021-01-08T21:08:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjk5NCMzOTEwOTg4IzIwODQ0OTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-johnson-lau-contracts-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CEO Dr. Johnson Lau Contracts COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}